ACRX stock forecast
Our latest prediction for AcelRx Pharmaceuticals, Inc.'s stock price was made on the June 5, 2019 when the stock price was at 2.31$.
In the short term (2weeks), ACRX's stock price should outperform the market by 7.20%. During that period the price should oscillate between -8.10% and +18.41%.
In the medium term (3months), ACRX's stock price should outperform the market by 11.47%. During that period the price should oscillate between -20.59% and +45.64%.Get email alerts
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.
At the moment the company generates 2M USD in revenues.
On its last earning announcement, the company reported a loss of -0.75$ per share.
The book value per share is -0.81$
Three months stock forecastJune 5, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|